Navigation Links
World TB Day Senate Briefing
Date:3/23/2010

WASHINGTON, March 23 /PRNewswire-USNewswire/ --

What:

A Senate briefing, Bringing Established Methods to Scale: New Perspectives in the Changing World of TB, to discuss TB and drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively-drug resistant (XDR-TB), the impact on global health and the current state of surveillance, diagnosis and treatment around the world.

Who:

Co-hosts include the Global Health Council, American Thoracic Society, Stop TB Partnership and The Lilly MDR-TB Partnership.

Speakers:

  • Dr. Ernesto Jaramillo, Team Leader for MDR-TB, Stop TB Department, World Health Organization
  • Dr. Rachel Nugent, Center for Global Development - MDR-TB and its relation to global health
  • Dr. Celine Gounder, Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) - The combined TB and HIV epidemic and the effects of community-based research

Moderator: Smita Baruah, Global Health Council

When:

World TB Day, Wednesday, March 24, 2010, 10:00 a.m.11:30 a.m. ET

Where:

Hart Senate Office Building, Room SH-902

Washington, DC

Why:

This year's World TB Day marks the midway point for the Global Plan to Stop TB. The plan's goals are to expand equitable access for all to quality TB diagnosis and treatment; to treat 50 million people; to save 14 million lives; to introduce in 2010 the first new TB drug in 40 years; to detect active TB through diagnostic tests at the point of care allowing rapid, sensitive and inexpensive detection by 2010; and to have a new, safe, effective and affordable vaccine by 2015.

Current TB statistics:

  • There were 9.4 million new TB cases in 2008, including 1.4 million cases among people living with HIV(1)
  • 1.8 million people died from TB in 2008, including 500,000 people with HIV - equal to 4,500 deaths a day(1)
  • TB is a leading killer of people with HIV(1)
  • Today's TB drugs are more than 40 years old and must be taken for at least six to nine months for drug-susceptible tuberculosis(2)
  • MDR-TB is a form of TB that is difficult and expensive to treat and fails to respond to standard first-line drugs. (1)  There were an estimated 500,000 new MDR-TB cases in 2007. Just over 1% of cases were receiving treatment in 2008 known to be based on WHO's recommended standards(1)
  • XDR-TB, which occurs when resistance to second-line drugs develops on top of MDR-TB, been found in 57 countries to date(1)

For more information, please go to http://www.globalhealth.org/news/article/12157

(1) "2009 Update Tuberculosis Facts;" http://www.who.int/tb/publications/2009/tbfactsheet_2009update_one_page.pdf  World Health Organization, Stop TB Partnership. 18 Mar. 2010

(2) "Mission and History;" http://www.tballiance.org/about/mission.php. TB Alliance. 18 Mar. 2010

SOURCE The Lilly MDR-TB Partnership

Back to top

RELATED LINKS
http://www.globalhealth.org/news/article/12157

'/>"/>

SOURCE The Lilly MDR-TB Partnership
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Pennsylvania Physician General Dr. Rachel Levine ... Gary Tennis released safe prescribing guidelines ... developed with the help of a task force. ... frequently prescribed for anxiety or insomnia," said Dr. ... pain medications, benzodiazepines pose a significant risk for ...
(Date:12/8/2016)... Information products and services provider Elsevier ... Scopus , the world,s largest abstract and citation database of peer-reviewed ... journals from over 5,000 publishers. The new set of metrics will ... and when to adjust a journal,s editorial strategy. ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, ... Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related to ... prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 with ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The ... ultimate weight loss and wellness program, at their world headquarters of Omni La Costa ... and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, or ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... its innovative Unified Instance Manager architecture, meeting the needs of multichannel growth ... optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational ...
(Date:12/8/2016)... ... ... STATEN ISLAND, N.Y., Nov. 24, 2016 — Richmond ... of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services from three ... , Among the recognitions, the American College of Surgeons' (ACS) named the hospital's ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
Breaking Medicine News(10 mins):